Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jessica Merrill

Senior Editor

New York, NY
Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest From Jessica Merrill

Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More

“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.

Leadership Policy

Commercial Fate Of Sarepta’s DMD Gene Therapy Remains Tied To EMBARK

The company guided investors to expect a narrow initial label under a US FDA accelerated approval for SRP-9001, with expansion possible based on EMBARK.

Gene Therapy FDA

CMS Official Calls Medicare Price Negotiations An ‘Ongoing Conversation’

The US Centers for Medicare & Medicaid Services’ Vinod Mitta discussed the agency’s latest thinking on the implementation of Medicare drug price negotiations at the Financial Times Pharma Summit.

Policy Politics

Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout

Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.

M & A Deals

Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III

A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.

Metabolic Disorders Research & Development

Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout

Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.

M & A Deals
See All
UsernamePublicRestriction

Register